NDA 211810 · Daiichi Sankyo INC
Turalio
Pexidartinib Hydrochloride · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Aug 2, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
29
2 Phase 3, 2 recruiting
FAERS reports
717
117 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct syndrome [see Warnings and Precautions (5.1) ] . Monitor liver tests prior to initiation of TURALIO and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue TURALIO based on severity of hepatotoxicity. Monitoring and prompt cessation of TURALIO may not eliminate the risk of serious and potentially fatal liver injury [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . TURALIO is available only through a restricted program called the TURALIO Risk Evaluation and Mitigation Strategy (REMS) Program [see Warnings and Precautions (5.2) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct...
What it is approved for
From the label in effect Jan 16, 2025.
TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. ( 1 )
Mechanism: Pexidartinib is a small molecule tyrosine kinase inhibitor that targets colony stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation. Overexpression of the CSF1R ligand promotes cell proliferation and accumulation in the synovium. In vitro, pexidartinib inhibited proliferation of cell lines dependent on CSF1R and ligand-induced autophosphorylation of CSF1R. Pexidartinib also inhibited the proliferation of a CSF1R dependent cell line in vivo.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 2022 Supplement 9 · Efficacy OrphanLetterLabel
- Oct 6, 2022 Supplement 8 · Efficacy OrphanLetter
- Aug 2, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- TURALIO · PEXIDARTINIB HYDROCHLORIDE EQ 125MG BASE · CAPSULE, ORAL · Prescription
- TURALIO · PEXIDARTINIB HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pexidartinib" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT01004861 · 132 participants · Start Oct 1, 2009 · Primary completion Jan 31, 2018
Drug: PLX3397 · For: Solid Tumor
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 13 sites in all
- Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)Pivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT02371369 · 120 participants · Start May 11, 2015 · Primary completion Mar 27, 2017
Drug: Pexidartinib; Placebo · For: Pigmented Villonodular Synovitis; Giant Cell Tumors of the Tendon Sheath; Tenosynovial Giant Cell Tumor
Sites: Scottsdale, Arizona; Los Angeles, California; Palo Alto, California · 39 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT01349049 · 90 participants · Start Nov 21, 2011 · Primary completion Jan 20, 2015
Drug: PLX3397; PLX3397 · For: Acute Myeloid Leukemia
Sites: San Francisco, California; Chicago, Illinois; Baltimore, Maryland · 9 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT02452424 · 78 participants · Start Jul 2, 2015 · Primary completion Aug 17, 2018
Drug: PLX3397; Pembrolizumab · For: Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck and 2 more
Sites: Scottsdale, Arizona; Greenbrae, California; Los Angeles, California · 12 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT01525602 · 74 participants · Start May 2012 · Primary completion Dec 2017
Drug: PLX3397; Paclitaxel · For: Solid Tumors
Sites: Birmingham, Alabama; San Francisco, California; Aurora, Colorado · 8 sites in all
Hope Rugo, MDAcademic, hospital or other
NCT01596751 · 67 participants · Start Jul 12, 2012 · Primary completion Jul 5, 2017
Drug: PLX3397; Eribulin · For: Metastatic Breast Cancer
Sites: San Francisco, California; Durham, North Carolina; Nashville, Tennessee
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT01790503 · 65 participants · Start Jul 18, 2013 · Primary completion Nov 3, 2017
Drug: PLX3397; Temozolomide · For: Patients With Newly Diagnosed Glioblastoma
Sites: Chicago, Illinois; Boston, Massachusetts; Detroit, Michigan · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue270
- fatigue251
- hair colour changes236
- nausea138
- pruritus113
- off label use106
- rash87
- therapy cessation81
- pain76
- headache72
- product dose omission in error69
- product use issue67
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 37 |
| 2020 | 109 |
| 2021 | 131 |
| 2022 | 115 |
| 2023 | 120 |
| 2024 | 105 |
| 2025 | 61 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Turalio (Pexidartinib Hydrochloride)
2024 spending
$2.4M
Beneficiaries
19
145 claims
Per beneficiary
$125,826
$188.99 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $916,537 |
| 2021 | $709,881 |
| 2022 | $1,148,375 |
| 2023 | $1,798,156 |
| 2024 | $2,390,695 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD, Gelderblom H, Palmerini E, et al. · Lancet 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
Healey JH, Tap WD, Gelhorn HL, et al. · Clin Orthop Relat Res 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
Robert M, Farese H, Miossec P · Front Immunol 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Desai J, Wagner AJ, Carrasco Garcia I, et al. · Cancer 2025 · Multicenter Study, Clinical Trial, Phase IV
- Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.
Wagner AJ, Tap WD, Bauer S, et al. · Oncologist 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Lee JH, Chen TW, Hsu CH, et al. · Invest New Drugs 2020 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Daiichi Sankyo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.